Navigation Links
CVS Caremark Study Finds Non-Adherent Heart Failure Patients Almost Twice as Likely to be Re-Hospitalized Within a Year
Date:2/3/2009

CVS Caremark Proactive Pharmacy Care approach designed to help improve medication adherence to positively impact outcomes and manage costs

WOONSOCKET, R.I., Feb. 3 /PRNewswire/ -- A study released today by CVS Caremark (NYSE: CVS) found that nearly half of patients hospitalized for heart failure may not be adherent to recommended drug therapies, significantly increasing their risk for subsequent hospitalization within 12 months. The study found that among those patients who were non-adherent to drug therapy, average subsequent hospitalizations per patient in a 12 month period (1.1 re-hospitalizations) were almost twice that of adherent patients (0.6 re-hospitalizations).

"The ongoing challenge of medication non-adherence for patients with heart conditions is well known and, as we see with many chronic conditions, medication adherence for heart failure patients is a significant driver of both long term clinical outcomes and cost impact," said Troyen A. Brennan, M.D., M.P.H., Executive Vice President and Chief Medical Officer, CVS Caremark. "To address this issue, CVS Caremark provides our PBM clients with adherence to drug therapy programs that proactively engage participants, achieve significant gains in converting patients to necessary therapies, improve medication adherence and maintain participant compliance over the long term."

The study examined adherence to key heart failure medications (ACE/ARBs, beta-blockers and diuretics) over the 12-months following a heart failure-related inpatient hospitalization. Results found that 49.9 percent of patients studied were not optimally adherent to their medications and had a medication possession ratio (MPR) of less than 0.80. Across all patients, 41% were re-hospitalized at least once within the 12-month follow-up period; however, the highest rate of re-hospitalization was observed for the non-adherent group.

The CVS Caremark Proactive Pharmacy Care approach is focused on achieving best-in-class results by changing patient behavior to encourage medication adherence and involves clinical interventions throughout the treatment cycle with the right tactics to engage each patient. The Adherence to Drug Therapy solution is a mail and retail based program designed to impact patient behavior through timely interventions that include face-to-face first fill counseling; IVR and Web refill reminders, renewals and pick-up prompts; outreach calls to potentially non-adherent patients from their local CVS pharmacist, to encourage restarting a maintenance medication and personalized letters about the importance of staying on a prescribed therapy sent to patients who have stopped filling a maintenance prescription and their health care provider. The Adherence to Drug Therapy solution helps approximately 88% of heart failure patients maintain optimal adherence to their medications.

In addition, CVS Caremark offers PBM clients the AccordantCare Health Management Program for Heart Failure, which provides a thorough evaluation of clinical tests and procedures based on nationally recognized guidelines that are recommended to enrolled patients and their health care provider.

"The strategies we employ at CVS Caremark to improve medication adherence for heart failure patients have proven benefits for health care outcomes and cost reduction for both the patient and the payor," said Dr. Brennan. "Following are some other key tips for heart failure patients and their caregivers: Make sure you take the medications prescribed by your doctor; Talk to your health care provider or pharmacist about how to manage side effects and stay on therapy; If cost is an issue, talk to your health care provider or pharmacist about whether less expensive generics are available and Sign-up for an auto-refill program with your retail or mail-order pharmacy to keep your prescription refills on track and on time."

The study evaluated de-identified data for more than 1,000 heart failure patients from CVS Caremark's Medical Claims Research Database who had an in-patient hospitalization for heart failure between April 1, 2006 and March 31, 2007. The follow-up period for subsequent hospitalizations was for the 12-months following the initial hospitalization date. All study participants were continuously eligible for medical and pharmacy benefits through the index and follow-up periods. The results from this analysis demonstrate a significant link between medication adherence and health services utilization. However, as in most observational studies, the causal nature of this relationship cannot be strictly determined.

About CVS Caremark

CVS Caremark is the largest provider of prescriptions in the nation. The Company fills or manages more than 1 billion prescriptions annually. Through its unmatched breadth of service offerings, CVS Caremark is transforming the delivery of health care services in the U.S. The Company is uniquely positioned to effectively manage costs and improve health care outcomes through its more than 6,800 CVS/pharmacy and Longs Drugs stores; its Caremark Pharmacy Services division (pharmacy benefit management, mail order and specialty pharmacy); its retail-based health clinic subsidiary, MinuteClinic; and its online pharmacy, CVS.com. General information about CVS Caremark is available through the Investor Relations section of the Company's Web site, at cvscaremark.com/investors, as well as through the press room section of the Company's Web site, at cvscaremark.com/newsroom.

    Media Contact:
    Steve Campanini
    CVS Caremark
    Corporate Communications
    (401) 770-5005

    Christine Cramer
    CVS Caremark
    Corporate Communications
    (401) 770-3317


'/>"/>
SOURCE CVS Caremark
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Mayo Clinic Study Finds Younger Men With Erectile Dysfunction at Double Risk of Heart Disease
2. First U.S. Patients Enrolled in the REALISM Continued Access Study
3. Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study
4. Study Shows Leconotide, an Investigative Calcium Channel Blocker, Has Potential as a Selective, Efficacious, Non-Opioid Pain Treatment
5. Study of Cannabinoid Medicine for Pain Found Patients Got High, but Effects Not Related to Pain Relief
6. Study Shows No Standardized Approach to Epidural Steroid Injections for Back Pain
7. ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
8. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
9. Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults
10. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
11. Study Shows How Defective DNA Repair Triggers Two Neurological Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):